Rajeev Vibhakar
Concepts (383)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Medulloblastoma | 36 | 2023 | 177 | 10.030 |
Why?
| Cerebellar Neoplasms | 26 | 2023 | 135 | 7.850 |
Why?
| Glioma | 14 | 2024 | 297 | 3.390 |
Why?
| Rhabdoid Tumor | 9 | 2022 | 80 | 2.980 |
Why?
| Brain Neoplasms | 20 | 2024 | 987 | 2.830 |
Why?
| Gene Expression Regulation, Neoplastic | 22 | 2022 | 1142 | 2.720 |
Why?
| Radiation Tolerance | 7 | 2022 | 100 | 2.590 |
Why?
| Cell Cycle Proteins | 8 | 2022 | 559 | 2.400 |
Why?
| Cell Proliferation | 24 | 2023 | 2197 | 1.820 |
Why?
| Teratoma | 5 | 2022 | 92 | 1.680 |
Why?
| Cell Line, Tumor | 29 | 2023 | 2756 | 1.620 |
Why?
| Protein-Tyrosine Kinases | 4 | 2020 | 399 | 1.470 |
Why?
| Pyrazoles | 7 | 2022 | 361 | 1.280 |
Why?
| Nuclear Proteins | 9 | 2023 | 591 | 1.270 |
Why?
| Proto-Oncogene Proteins c-myc | 4 | 2021 | 114 | 1.260 |
Why?
| Ependymoma | 9 | 2020 | 159 | 1.190 |
Why?
| Proto-Oncogene Proteins | 4 | 2022 | 604 | 1.180 |
Why?
| Apoptosis | 18 | 2022 | 2363 | 1.150 |
Why?
| Biomarkers, Tumor | 9 | 2021 | 1045 | 1.140 |
Why?
| Pyrimidines | 8 | 2019 | 377 | 1.060 |
Why?
| Molecular Targeted Therapy | 4 | 2021 | 351 | 1.030 |
Why?
| Cyclin-Dependent Kinase 6 | 4 | 2020 | 37 | 1.020 |
Why?
| Antineoplastic Agents | 10 | 2022 | 1890 | 1.000 |
Why?
| Brain Stem Neoplasms | 4 | 2021 | 87 | 1.000 |
Why?
| Radiation-Sensitizing Agents | 2 | 2016 | 38 | 0.950 |
Why?
| Cell Transformation, Neoplastic | 2 | 2019 | 304 | 0.920 |
Why?
| MicroRNAs | 5 | 2020 | 615 | 0.880 |
Why?
| Genes, myc | 3 | 2020 | 45 | 0.880 |
Why?
| Cellular Senescence | 3 | 2019 | 150 | 0.870 |
Why?
| Pyrimidinones | 4 | 2020 | 86 | 0.870 |
Why?
| Hedgehog Proteins | 7 | 2022 | 171 | 0.860 |
Why?
| Cell Cycle | 11 | 2017 | 541 | 0.800 |
Why?
| Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 56 | 0.790 |
Why?
| Receptor, trkC | 1 | 2021 | 10 | 0.770 |
Why?
| Receptor, trkB | 1 | 2021 | 28 | 0.760 |
Why?
| Anilides | 3 | 2019 | 67 | 0.750 |
Why?
| Gene Expression Profiling | 15 | 2024 | 1567 | 0.730 |
Why?
| Jumonji Domain-Containing Histone Demethylases | 1 | 2021 | 59 | 0.730 |
Why?
| Central Nervous System Neoplasms | 4 | 2019 | 125 | 0.730 |
Why?
| Neoplastic Stem Cells | 3 | 2019 | 330 | 0.730 |
Why?
| SMARCB1 Protein | 2 | 2020 | 17 | 0.710 |
Why?
| Transcriptional Elongation Factors | 1 | 2020 | 33 | 0.710 |
Why?
| DNA Repair | 1 | 2021 | 195 | 0.680 |
Why?
| Deoxycytidine | 1 | 2020 | 136 | 0.670 |
Why?
| Pteridines | 2 | 2016 | 21 | 0.660 |
Why?
| Membrane Glycoproteins | 1 | 2021 | 429 | 0.650 |
Why?
| Cerebellum | 5 | 2022 | 201 | 0.640 |
Why?
| Humans | 81 | 2024 | 115297 | 0.630 |
Why?
| Glioblastoma | 3 | 2023 | 256 | 0.630 |
Why?
| Transcription Factors | 6 | 2023 | 1531 | 0.620 |
Why?
| Histones | 4 | 2020 | 535 | 0.620 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2022 | 442 | 0.620 |
Why?
| Oligonucleotide Array Sequence Analysis | 10 | 2016 | 757 | 0.620 |
Why?
| RNA, Small Interfering | 4 | 2022 | 546 | 0.570 |
Why?
| Vinblastine | 1 | 2016 | 61 | 0.570 |
Why?
| Blotting, Western | 8 | 2019 | 1146 | 0.560 |
Why?
| Checkpoint Kinase 1 | 1 | 2016 | 27 | 0.560 |
Why?
| Vincristine | 1 | 2016 | 96 | 0.550 |
Why?
| Bilirubin | 1 | 2016 | 91 | 0.550 |
Why?
| Radiation, Ionizing | 3 | 2022 | 73 | 0.550 |
Why?
| Cell Survival | 8 | 2019 | 1011 | 0.540 |
Why?
| Tumor Cells, Cultured | 7 | 2020 | 840 | 0.520 |
Why?
| Mutation | 7 | 2022 | 3371 | 0.520 |
Why?
| Enzyme Inhibitors | 6 | 2020 | 749 | 0.520 |
Why?
| Chemical and Drug Induced Liver Injury | 1 | 2016 | 134 | 0.510 |
Why?
| Transcriptome | 5 | 2022 | 745 | 0.500 |
Why?
| Polycomb Repressive Complex 2 | 2 | 2012 | 59 | 0.500 |
Why?
| Child | 29 | 2024 | 18435 | 0.500 |
Why?
| RNA, Messenger | 7 | 2014 | 2579 | 0.470 |
Why?
| Histone Deacetylase Inhibitors | 3 | 2023 | 199 | 0.470 |
Why?
| Repressor Proteins | 3 | 2022 | 370 | 0.420 |
Why?
| Child, Preschool | 18 | 2021 | 9124 | 0.400 |
Why?
| Mice | 14 | 2023 | 15075 | 0.390 |
Why?
| Prognosis | 9 | 2020 | 3337 | 0.390 |
Why?
| Piperazines | 3 | 2022 | 314 | 0.390 |
Why?
| Epigenesis, Genetic | 4 | 2021 | 534 | 0.380 |
Why?
| Azepines | 3 | 2019 | 67 | 0.380 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2014 | 942 | 0.360 |
Why?
| Chromatin | 4 | 2020 | 427 | 0.360 |
Why?
| Intracellular Space | 1 | 2010 | 68 | 0.360 |
Why?
| Neoplasms, Neuroepithelial | 2 | 2020 | 17 | 0.360 |
Why?
| Genes, Tumor Suppressor | 2 | 2007 | 75 | 0.350 |
Why?
| Neoplasm Proteins | 2 | 2012 | 387 | 0.350 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 1359 | 0.350 |
Why?
| Cisplatin | 3 | 2016 | 265 | 0.350 |
Why?
| Reactive Oxygen Species | 2 | 2022 | 548 | 0.340 |
Why?
| Xenograft Model Antitumor Assays | 5 | 2020 | 716 | 0.340 |
Why?
| Cell Differentiation | 6 | 2022 | 1710 | 0.330 |
Why?
| Real-Time Polymerase Chain Reaction | 4 | 2014 | 323 | 0.330 |
Why?
| Drug Screening Assays, Antitumor | 4 | 2021 | 180 | 0.320 |
Why?
| Protein Kinase Inhibitors | 2 | 2014 | 788 | 0.320 |
Why?
| Chromosomes, Human, Pair 1 | 2 | 2019 | 71 | 0.320 |
Why?
| Animals | 15 | 2023 | 32091 | 0.310 |
Why?
| Infratentorial Neoplasms | 2 | 2019 | 46 | 0.310 |
Why?
| NF-kappa B | 4 | 2023 | 634 | 0.310 |
Why?
| Quinazolines | 2 | 2022 | 241 | 0.310 |
Why?
| DNA-Binding Proteins | 3 | 2017 | 1308 | 0.300 |
Why?
| Single-Cell Analysis | 4 | 2022 | 180 | 0.290 |
Why?
| B7 Antigens | 2 | 2020 | 9 | 0.290 |
Why?
| Mice, Nude | 3 | 2020 | 641 | 0.290 |
Why?
| Signal Transduction | 9 | 2021 | 4537 | 0.290 |
Why?
| Aurora Kinases | 3 | 2012 | 28 | 0.290 |
Why?
| Aurora Kinase A | 3 | 2012 | 50 | 0.280 |
Why?
| Combined Modality Therapy | 6 | 2019 | 1136 | 0.280 |
Why?
| Proto-Oncogene Proteins B-raf | 2 | 2019 | 191 | 0.280 |
Why?
| Neoplasm Recurrence, Local | 4 | 2022 | 864 | 0.270 |
Why?
| Enhancer of Zeste Homolog 2 Protein | 3 | 2023 | 37 | 0.270 |
Why?
| Polycomb Repressive Complex 1 | 2 | 2020 | 41 | 0.270 |
Why?
| Autophagy | 2 | 2019 | 236 | 0.270 |
Why?
| Triazoles | 2 | 2019 | 125 | 0.260 |
Why?
| Epigenomics | 3 | 2020 | 106 | 0.260 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2007 | 347 | 0.250 |
Why?
| Bone Morphogenetic Proteins | 2 | 2019 | 135 | 0.250 |
Why?
| Cord Blood Stem Cell Transplantation | 1 | 2005 | 91 | 0.240 |
Why?
| Survival Rate | 5 | 2020 | 1663 | 0.240 |
Why?
| Abnormalities, Multiple | 1 | 2005 | 176 | 0.230 |
Why?
| Drug Resistance, Neoplasm | 2 | 2019 | 646 | 0.230 |
Why?
| Female | 23 | 2021 | 59773 | 0.230 |
Why?
| Metencephalon | 1 | 2022 | 1 | 0.220 |
Why?
| Cell Lineage | 2 | 2022 | 311 | 0.220 |
Why?
| Disease-Free Survival | 3 | 2016 | 625 | 0.210 |
Why?
| von Willebrand Diseases | 1 | 2022 | 11 | 0.210 |
Why?
| G2 Phase Cell Cycle Checkpoints | 1 | 2022 | 41 | 0.210 |
Why?
| Spheroids, Cellular | 2 | 2012 | 56 | 0.210 |
Why?
| von Willebrand Factor | 1 | 2022 | 55 | 0.200 |
Why?
| Genome, Human | 3 | 2014 | 372 | 0.200 |
Why?
| DNA Copy Number Variations | 4 | 2021 | 156 | 0.200 |
Why?
| Tumor Microenvironment | 2 | 2022 | 440 | 0.200 |
Why?
| Pyridines | 3 | 2019 | 417 | 0.200 |
Why?
| Radiation | 1 | 2021 | 25 | 0.200 |
Why?
| Neural Stem Cells | 2 | 2012 | 115 | 0.190 |
Why?
| Mice, Transgenic | 3 | 2021 | 1973 | 0.190 |
Why?
| RNA, Long Noncoding | 2 | 2021 | 158 | 0.180 |
Why?
| Fatal Outcome | 1 | 2021 | 282 | 0.180 |
Why?
| Receptor, EphB4 | 1 | 2020 | 29 | 0.180 |
Why?
| Antigens, Surface | 2 | 1997 | 150 | 0.180 |
Why?
| Ephrin-B2 | 1 | 2020 | 42 | 0.180 |
Why?
| Colony-Forming Units Assay | 2 | 2012 | 92 | 0.180 |
Why?
| Craniospinal Irradiation | 1 | 2019 | 4 | 0.180 |
Why?
| Neoplastic Cells, Circulating | 1 | 2020 | 58 | 0.180 |
Why?
| Oncogene Proteins, Fusion | 2 | 2019 | 177 | 0.170 |
Why?
| Receptors, Nerve Growth Factor | 1 | 2019 | 15 | 0.170 |
Why?
| RNA, Small Nuclear | 1 | 2019 | 31 | 0.170 |
Why?
| Dose-Response Relationship, Drug | 3 | 2017 | 1855 | 0.170 |
Why?
| Karyopherins | 1 | 2019 | 15 | 0.170 |
Why?
| Adolescent | 12 | 2021 | 17767 | 0.170 |
Why?
| Benzamides | 3 | 2019 | 170 | 0.170 |
Why?
| Kaplan-Meier Estimate | 3 | 2017 | 825 | 0.170 |
Why?
| Male | 20 | 2021 | 55796 | 0.170 |
Why?
| Infant | 12 | 2021 | 7955 | 0.170 |
Why?
| Phenotype | 3 | 2024 | 2854 | 0.170 |
Why?
| Proteins | 3 | 2021 | 917 | 0.170 |
Why?
| Cell Self Renewal | 1 | 2019 | 50 | 0.160 |
Why?
| Gene Expression Regulation, Developmental | 2 | 2021 | 798 | 0.160 |
Why?
| Chemoradiotherapy | 1 | 2019 | 197 | 0.160 |
Why?
| Base Sequence | 4 | 2012 | 2104 | 0.160 |
Why?
| Receptors, Cytoplasmic and Nuclear | 1 | 2019 | 196 | 0.150 |
Why?
| Cohort Studies | 6 | 2021 | 4960 | 0.150 |
Why?
| Sulfonamides | 2 | 2022 | 446 | 0.150 |
Why?
| DNA Methylation | 4 | 2021 | 505 | 0.150 |
Why?
| Everolimus | 1 | 2017 | 63 | 0.150 |
Why?
| Recombinational DNA Repair | 1 | 2017 | 10 | 0.150 |
Why?
| Genes, p16 | 1 | 2017 | 17 | 0.150 |
Why?
| DNA Damage | 2 | 2017 | 348 | 0.150 |
Why?
| E2F Transcription Factors | 1 | 2017 | 55 | 0.150 |
Why?
| Morpholines | 1 | 2017 | 99 | 0.140 |
Why?
| Phthalazines | 1 | 2017 | 43 | 0.140 |
Why?
| Chromosome Aberrations | 1 | 2017 | 130 | 0.140 |
Why?
| Cell Division | 2 | 2010 | 752 | 0.140 |
Why?
| Chloroquine | 1 | 2017 | 52 | 0.140 |
Why?
| Stem Cells | 1 | 2021 | 542 | 0.140 |
Why?
| Benzodiazepinones | 1 | 2016 | 14 | 0.140 |
Why?
| Immunophenotyping | 1 | 2017 | 272 | 0.140 |
Why?
| M Phase Cell Cycle Checkpoints | 1 | 2016 | 23 | 0.140 |
Why?
| Electric Stimulation Therapy | 1 | 2017 | 56 | 0.140 |
Why?
| Up-Regulation | 2 | 2016 | 818 | 0.140 |
Why?
| Neoplasm Invasiveness | 2 | 2020 | 446 | 0.140 |
Why?
| Microarray Analysis | 2 | 2017 | 118 | 0.140 |
Why?
| Urea | 1 | 2016 | 69 | 0.140 |
Why?
| Lysine | 2 | 2020 | 245 | 0.130 |
Why?
| Cancer Survivors | 1 | 2019 | 200 | 0.130 |
Why?
| Thiophenes | 1 | 2016 | 106 | 0.130 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 396 | 0.130 |
Why?
| Mitosis | 1 | 2016 | 167 | 0.130 |
Why?
| Genomics | 3 | 2017 | 638 | 0.130 |
Why?
| Survival Analysis | 2 | 2010 | 1218 | 0.130 |
Why?
| Antineoplastic Agents, Phytogenic | 1 | 2016 | 180 | 0.130 |
Why?
| Tumor Suppressor Proteins | 1 | 2017 | 282 | 0.130 |
Why?
| HeLa Cells | 1 | 2016 | 564 | 0.120 |
Why?
| Promoter Regions, Genetic | 3 | 2017 | 1127 | 0.120 |
Why?
| Indoles | 1 | 2017 | 307 | 0.120 |
Why?
| Lymphocyte Activation | 2 | 2002 | 1051 | 0.120 |
Why?
| Brain | 2 | 2020 | 2371 | 0.120 |
Why?
| Flow Cytometry | 2 | 2019 | 1045 | 0.120 |
Why?
| STAT3 Transcription Factor | 1 | 2015 | 178 | 0.110 |
Why?
| Precision Medicine | 1 | 2017 | 352 | 0.110 |
Why?
| Sequence Analysis, DNA | 1 | 2016 | 730 | 0.110 |
Why?
| Cell Movement | 2 | 2020 | 869 | 0.110 |
Why?
| Phosphorylation | 4 | 2020 | 1569 | 0.110 |
Why?
| Cathepsin B | 1 | 2012 | 14 | 0.110 |
Why?
| Rapamycin-Insensitive Companion of mTOR Protein | 1 | 2012 | 28 | 0.110 |
Why?
| Argonaute Proteins | 1 | 2012 | 28 | 0.110 |
Why?
| Wnt Proteins | 1 | 2014 | 139 | 0.110 |
Why?
| Genomic Structural Variation | 1 | 2012 | 7 | 0.110 |
Why?
| Quality of Life | 2 | 2023 | 2384 | 0.110 |
Why?
| Dose-Response Relationship, Radiation | 1 | 2012 | 129 | 0.110 |
Why?
| Retrospective Studies | 5 | 2019 | 12588 | 0.110 |
Why?
| Acetylcysteine | 1 | 2013 | 149 | 0.110 |
Why?
| Immunoenzyme Techniques | 1 | 2012 | 192 | 0.100 |
Why?
| Colorado | 1 | 2022 | 4033 | 0.100 |
Why?
| Luciferases | 1 | 2012 | 136 | 0.100 |
Why?
| 3' Untranslated Regions | 1 | 2012 | 139 | 0.100 |
Why?
| Gene Expression Regulation | 1 | 2021 | 2366 | 0.100 |
Why?
| Carrier Proteins | 2 | 2012 | 706 | 0.100 |
Why?
| Tubulin | 1 | 2012 | 122 | 0.100 |
Why?
| Histone-Lysine N-Methyltransferase | 1 | 2012 | 98 | 0.100 |
Why?
| Telomerase | 1 | 2013 | 203 | 0.100 |
Why?
| Interleukin-6 | 1 | 2015 | 668 | 0.100 |
Why?
| Acetylation | 1 | 2011 | 212 | 0.100 |
Why?
| Leukemia, Myeloid, Acute | 1 | 2017 | 531 | 0.090 |
Why?
| RNA Interference | 1 | 2012 | 441 | 0.090 |
Why?
| Adenosine | 1 | 2012 | 202 | 0.090 |
Why?
| Acetaminophen | 1 | 2013 | 240 | 0.090 |
Why?
| Aging | 1 | 2020 | 1636 | 0.090 |
Why?
| Radiosurgery | 1 | 2014 | 311 | 0.090 |
Why?
| Disease Models, Animal | 1 | 2019 | 3565 | 0.090 |
Why?
| Tyrosine | 2 | 2023 | 214 | 0.090 |
Why?
| Ki-67 Antigen | 2 | 2022 | 104 | 0.090 |
Why?
| Hydroxamic Acids | 2 | 2007 | 80 | 0.090 |
Why?
| Neoplasm Grading | 2 | 2021 | 246 | 0.090 |
Why?
| Superoxides | 1 | 2010 | 191 | 0.090 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2012 | 447 | 0.090 |
Why?
| Gene Silencing | 2 | 2007 | 176 | 0.080 |
Why?
| T-Lymphocytes | 1 | 1997 | 1751 | 0.080 |
Why?
| Kidney Neoplasms | 1 | 2013 | 323 | 0.080 |
Why?
| Histone Demethylases | 2 | 2022 | 28 | 0.080 |
Why?
| Cluster Analysis | 3 | 2017 | 469 | 0.080 |
Why?
| Down-Regulation | 1 | 2010 | 603 | 0.080 |
Why?
| Syndrome | 2 | 2005 | 337 | 0.070 |
Why?
| Young Adult | 5 | 2021 | 10413 | 0.070 |
Why?
| Neoplasms | 1 | 2021 | 2110 | 0.070 |
Why?
| Nerve Tissue Proteins | 2 | 2012 | 538 | 0.070 |
Why?
| In Situ Hybridization, Fluorescence | 2 | 2021 | 305 | 0.070 |
Why?
| Scrotum | 1 | 2006 | 25 | 0.070 |
Why?
| Premedication | 1 | 2005 | 36 | 0.070 |
Why?
| RNA | 1 | 2012 | 816 | 0.070 |
Why?
| Exocrine Pancreatic Insufficiency | 1 | 2005 | 17 | 0.070 |
Why?
| Drug Synergism | 2 | 2017 | 314 | 0.070 |
Why?
| Transplantation Chimera | 1 | 2005 | 51 | 0.070 |
Why?
| Computer Simulation | 2 | 2021 | 889 | 0.070 |
Why?
| Neuroblastoma | 1 | 2006 | 130 | 0.070 |
Why?
| Anemia, Aplastic | 1 | 2005 | 29 | 0.060 |
Why?
| Testicular Neoplasms | 1 | 2006 | 95 | 0.060 |
Why?
| Case-Control Studies | 1 | 2012 | 3035 | 0.060 |
Why?
| Molecular Sequence Data | 2 | 2008 | 2773 | 0.060 |
Why?
| Neutropenia | 1 | 2005 | 127 | 0.060 |
Why?
| Transplantation Conditioning | 1 | 2005 | 149 | 0.060 |
Why?
| Genetic Predisposition to Disease | 1 | 2012 | 2202 | 0.060 |
Why?
| Graft vs Host Disease | 1 | 2005 | 209 | 0.060 |
Why?
| Graft Survival | 1 | 2005 | 481 | 0.060 |
Why?
| Core Binding Factor alpha Subunits | 1 | 2022 | 1 | 0.050 |
Why?
| Protein Tyrosine Phosphatases | 1 | 2023 | 143 | 0.050 |
Why?
| Otx Transcription Factors | 1 | 2022 | 12 | 0.050 |
Why?
| Weibel-Palade Bodies | 1 | 2022 | 3 | 0.050 |
Why?
| T-Box Domain Proteins | 1 | 2022 | 94 | 0.050 |
Why?
| Lymphoproliferative Disorders | 1 | 2002 | 46 | 0.050 |
Why?
| fas Receptor | 1 | 2002 | 93 | 0.050 |
Why?
| Gene Ontology | 1 | 2021 | 45 | 0.050 |
Why?
| Human Umbilical Vein Endothelial Cells | 1 | 2022 | 91 | 0.050 |
Why?
| Antigens, CD | 3 | 2002 | 442 | 0.050 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 209 | 0.050 |
Why?
| Genetic Heterogeneity | 1 | 2021 | 56 | 0.050 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2023 | 390 | 0.050 |
Why?
| Phagocytosis | 1 | 2023 | 355 | 0.050 |
Why?
| Follow-Up Studies | 2 | 2019 | 4436 | 0.050 |
Why?
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2022 | 171 | 0.050 |
Why?
| Muscle Proteins | 1 | 2022 | 215 | 0.050 |
Why?
| Risk Factors | 3 | 2021 | 8684 | 0.050 |
Why?
| Ifosfamide | 1 | 2020 | 32 | 0.050 |
Why?
| Adult | 5 | 2021 | 30576 | 0.050 |
Why?
| Transcription Factor HES-1 | 1 | 2019 | 4 | 0.040 |
Why?
| Smoothened Receptor | 1 | 2019 | 5 | 0.040 |
Why?
| MyoD Protein | 1 | 2019 | 27 | 0.040 |
Why?
| Cyclophosphamide | 1 | 2020 | 217 | 0.040 |
Why?
| Gain of Function Mutation | 1 | 2019 | 30 | 0.040 |
Why?
| Astrocytoma | 1 | 2020 | 109 | 0.040 |
Why?
| RNA Splice Sites | 1 | 2019 | 32 | 0.040 |
Why?
| Apoptosis Regulatory Proteins | 2 | 1997 | 174 | 0.040 |
Why?
| Carcinogenesis | 1 | 2021 | 180 | 0.040 |
Why?
| Gene Regulatory Networks | 1 | 2021 | 236 | 0.040 |
Why?
| Mice, SCID | 1 | 2019 | 321 | 0.040 |
Why?
| Aminopyridines | 1 | 2019 | 82 | 0.040 |
Why?
| Autoimmune Diseases | 1 | 2002 | 392 | 0.040 |
Why?
| Programmed Cell Death 1 Receptor | 2 | 1997 | 195 | 0.040 |
Why?
| Consensus | 1 | 2021 | 531 | 0.040 |
Why?
| Receptors, Antigen, T-Cell | 1 | 2002 | 629 | 0.040 |
Why?
| RNA Splicing | 1 | 2019 | 244 | 0.040 |
Why?
| Alternative Splicing | 1 | 2019 | 186 | 0.040 |
Why?
| Treatment Outcome | 3 | 2017 | 9127 | 0.040 |
Why?
| Mice, Inbred NOD | 1 | 2019 | 559 | 0.040 |
Why?
| Drug Approval | 1 | 2018 | 76 | 0.040 |
Why?
| Receptors, HIV | 1 | 2017 | 23 | 0.040 |
Why?
| Mucin-1 | 1 | 2017 | 18 | 0.040 |
Why?
| Cytogenetic Analysis | 1 | 2017 | 29 | 0.040 |
Why?
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2017 | 57 | 0.040 |
Why?
| Homeodomain Proteins | 1 | 2021 | 465 | 0.040 |
Why?
| Global Health | 1 | 2019 | 292 | 0.040 |
Why?
| Transfection | 1 | 2019 | 858 | 0.040 |
Why?
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2017 | 99 | 0.040 |
Why?
| Tetradecanoylphorbol Acetate | 1 | 1997 | 151 | 0.040 |
Why?
| DNA, Complementary | 1 | 1997 | 260 | 0.040 |
Why?
| Glial Fibrillary Acidic Protein | 1 | 2017 | 82 | 0.040 |
Why?
| Jurkat Cells | 1 | 1997 | 130 | 0.040 |
Why?
| Microscopy, Confocal | 1 | 2017 | 298 | 0.030 |
Why?
| Radiotherapy | 1 | 2017 | 185 | 0.030 |
Why?
| Genetic Variation | 1 | 2021 | 888 | 0.030 |
Why?
| Macrophages | 1 | 2023 | 1273 | 0.030 |
Why?
| Transcriptional Activation | 1 | 2017 | 334 | 0.030 |
Why?
| Cell Culture Techniques | 1 | 2017 | 346 | 0.030 |
Why?
| Canada | 1 | 2016 | 336 | 0.030 |
Why?
| Lipopolysaccharide Receptors | 1 | 2015 | 86 | 0.030 |
Why?
| Health Status | 1 | 2019 | 728 | 0.030 |
Why?
| Hematopoietic Stem Cells | 1 | 1997 | 356 | 0.030 |
Why?
| Middle Aged | 3 | 2021 | 26936 | 0.030 |
Why?
| Zinc Finger Protein Gli2 | 1 | 2014 | 3 | 0.030 |
Why?
| Cytogenetics | 1 | 2014 | 9 | 0.030 |
Why?
| Chromosomes, Human, Pair 14 | 1 | 2014 | 17 | 0.030 |
Why?
| Tissue Array Analysis | 1 | 2014 | 49 | 0.030 |
Why?
| Myeloid Cells | 1 | 2015 | 127 | 0.030 |
Why?
| Chromosomes, Human, Pair 11 | 1 | 2014 | 65 | 0.030 |
Why?
| Imaging, Three-Dimensional | 1 | 2017 | 493 | 0.030 |
Why?
| Kruppel-Like Transcription Factors | 1 | 2014 | 61 | 0.030 |
Why?
| Membrane Potential, Mitochondrial | 1 | 2013 | 55 | 0.030 |
Why?
| Gene Expression | 2 | 2010 | 1451 | 0.030 |
Why?
| Magnetic Resonance Imaging | 2 | 2016 | 3070 | 0.030 |
Why?
| Drug Evaluation, Preclinical | 1 | 2013 | 168 | 0.030 |
Why?
| Immunohistochemistry | 1 | 2017 | 1634 | 0.030 |
Why?
| DNA Mutational Analysis | 1 | 2013 | 372 | 0.030 |
Why?
| B-Lymphocytes | 1 | 1997 | 770 | 0.030 |
Why?
| Gene Duplication | 1 | 2012 | 61 | 0.030 |
Why?
| Monocytes | 1 | 2015 | 501 | 0.030 |
Why?
| Inflammation | 1 | 2023 | 2482 | 0.030 |
Why?
| Methylation | 1 | 2012 | 202 | 0.030 |
Why?
| Translocation, Genetic | 1 | 2012 | 88 | 0.030 |
Why?
| Inflammation Mediators | 1 | 2015 | 475 | 0.030 |
Why?
| Glutathione | 1 | 2013 | 302 | 0.030 |
Why?
| Mice, Inbred C57BL | 1 | 2021 | 4770 | 0.020 |
Why?
| Proportional Hazards Models | 1 | 2014 | 1093 | 0.020 |
Why?
| Genome | 1 | 2012 | 258 | 0.020 |
Why?
| Age Factors | 1 | 2017 | 2908 | 0.020 |
Why?
| Transforming Growth Factor beta | 1 | 2012 | 447 | 0.020 |
Why?
| Predictive Value of Tests | 1 | 2014 | 1805 | 0.020 |
Why?
| Disease Progression | 1 | 2016 | 2423 | 0.020 |
Why?
| Genotype | 1 | 2013 | 1832 | 0.020 |
Why?
| Surveys and Questionnaires | 1 | 2019 | 4635 | 0.020 |
Why?
| Cytokines | 1 | 2015 | 1837 | 0.020 |
Why?
| Reproducibility of Results | 1 | 2014 | 2811 | 0.020 |
Why?
| Azacitidine | 1 | 2006 | 127 | 0.020 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2012 | 2016 | 0.020 |
Why?
| Risk Assessment | 1 | 2014 | 2988 | 0.020 |
Why?
| Tomography, X-Ray Computed | 1 | 2012 | 2401 | 0.010 |
Why?
| Antigens, Differentiation, T-Lymphocyte | 1 | 2002 | 84 | 0.010 |
Why?
| Lectins, C-Type | 1 | 2002 | 62 | 0.010 |
Why?
| Receptors, Interleukin-2 | 1 | 2002 | 65 | 0.010 |
Why?
| Cytoplasm | 1 | 2002 | 257 | 0.010 |
Why?
| Interleukin-4 | 1 | 2002 | 213 | 0.010 |
Why?
| Interleukin-2 | 1 | 2002 | 413 | 0.010 |
Why?
| Infant, Newborn | 1 | 2011 | 5060 | 0.010 |
Why?
| T-Lymphocyte Subsets | 1 | 2002 | 383 | 0.010 |
Why?
| T-Lymphocytes, Regulatory | 1 | 2002 | 347 | 0.010 |
Why?
| Interferon-gamma | 1 | 2002 | 725 | 0.010 |
Why?
| Restriction Mapping | 1 | 1997 | 73 | 0.010 |
Why?
| Chromosomes, Human, Pair 2 | 1 | 1997 | 28 | 0.010 |
Why?
| Sequence Homology, Nucleic Acid | 1 | 1997 | 148 | 0.010 |
Why?
| Interleukin-7 | 1 | 1997 | 44 | 0.010 |
Why?
| Regulatory Sequences, Nucleic Acid | 1 | 1997 | 77 | 0.010 |
Why?
| Genes | 1 | 1997 | 220 | 0.010 |
Why?
| Sequence Homology, Amino Acid | 1 | 1997 | 352 | 0.010 |
Why?
| Calcium | 1 | 2002 | 1107 | 0.010 |
Why?
| Bone Marrow | 1 | 1997 | 247 | 0.010 |
Why?
| Mice, Inbred BALB C | 1 | 1997 | 1164 | 0.010 |
Why?
| Amino Acid Sequence | 1 | 1997 | 1998 | 0.010 |
Why?
| Cells, Cultured | 1 | 1997 | 3879 | 0.010 |
Why?
|
|
Vibhakar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|